Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Evaluation of a Cincalcet Suppression Test
- Conditions
- Interventions
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 36
- Registration Number
- NCT01103206
- Locations
- 🇫🇷
University hospital, Rouen, Haute Normandie, France
Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT01101113
- Locations
- 🇰🇷
Hallym University Sacred Hospital, Pyungchon, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01011114
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 176
- Registration Number
- NCT01011699
- Locations
- 🇫🇷
ALURAD, Limoges, Limousin, France
🇫🇷Centre Hospital-Universitaire d'Amiens, Amiens, Picardie, France
🇫🇷Centre Hospitalier, Cambrai, France
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 272
- Registration Number
- NCT00977080
- Locations
- 🇺🇸
Site Reference ID/Investigator# 22781, Tempe, Arizona, United States
🇺🇸Site Reference ID/Investigator# 21144, St. Louis, Missouri, United States
🇺🇸Site Reference ID/Investigator# 22770, Philadelphia, Pennsylvania, United States
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 114
- Registration Number
- NCT00975000
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
- Conditions
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT00975221
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 78
- Registration Number
- NCT00936650
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00936988
PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 305
- Registration Number
- NCT00928408
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.